The carrying amount of goodwill at December 31, 2019 and March 31, 2019 was $32.6 million and $32.6 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, in May 2005 and ECP and AIS in July 2014. The carrying value of goodwill and the change in the balance for the nine months ended December 31, 2019 are as follows:

The Company evaluates goodwill at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. The Company has no accumulated impairment losses on goodwill.

The carrying amount of in-process research & development, or IPR&D, assets at December 31, 2019 and March 31, 2019 was $15.2 million for each date, respectively, and was recorded in conjunction with the Company’s acquisition of ECP and AIS, in July 2014. The estimated fair value of IPR&D assets at the acquisition date was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flow estimates for the future Impella ECP^TM expandable catheter pump technology was based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used an original discount rate of 21% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes is appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the nine months ended December 31, 2019 are as follows:

The Company evaluates IPR&D assets at least annually at October 31, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. The Company has no accumulated impairment losses on IPR&D assets.

	December 31, 2019		March 31, 2019
	(in $000's)
Equity method and other investments	$	117,036	$	80,779
Right of use asset - leases (Note 8)		11,455		—
Other intangible assets and other assets		6,676		4,336
Total other assets	$	135,167	$	85,115

The Company periodically makes investments in medical device companies that focus on heart failure, heart pump and other medical device technologies. For investments in convertible debt or preferred stock securities that do not have readily determinable market values, the Company measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment. The Company measures investments in equity securities at fair value and recognize changes in fair value in net income. For equity method investments, the amount of the Company’s initial investment is adjusted each period by the Company’s share of the investee’s income or loss. The Company monitors any events or changes in circumstances that may have a significant effect on the fair value of investments, either due to impairment or based on observable price changes, and makes any necessary adjustments.

The following table summarizes the Company’s equity method and other investments as of December 31, 2019 and March 31, 2019, which are classified as other assets in the consolidated balance sheets:

	December 31, 2019		March 31, 2019
	(in $000's)
Other investments	$	114,169	$	80,779
Equity method investment		2,867		—
Total equity and other investments	$	117,036	$	80,779

The carrying value of the Company’s portfolio of equity method and other investments and the change in the balance for the three and nine months ended December 31, 2019 and 2018 are as follows:

	For the Three Months Ended December 31,					For the Nine Months Ended December 31,
		2019			2018		2019			2018
	(in $000's)
Beginning balance	$	81,836		$	22,325	$	80,779		$	12,649
Additions		12,600			18,459		19,600			28,135
Disposals		(750	)		—		(750	)		—
Change in fair value, net		23,350			—		17,407			—
Ending balance	$	117,036		$	40,784	$	117,036		$	40,784

In fiscal 2019, the Company invested $25.0 million in Shockwave Medical. The fair value of this investment as of December 31, 2019 and March 31, 2019 was $73.7 million and $56.2 million, respectively. The Company recognized a pre-tax unrealized gain of $23.5 million and $17.5 million on its investment in Shockwave Medical for the three and nine months ended December 31, 2019, respectively.

In July 2019, the Company invested $3.0 million in a small private medical device company. Based on the Company’s controlling economic interest and significant influence exertion over the investee’s operating and financial policies, this investment was accounted for using the equity method. The Company recognizes its share of the results of operations related to this equity method investment one quarter in arrears when the results of the entity become available, in other income (expense), net of tax in the condensed consolidated statement of operations. The Company's share of income statement activity for this equity method investment for the three and nine months ended December 31, 2019 was a loss of $0.1 million.

During the nine months ended December 31, 2019, the Company made additional other investments of $16.6 million in other private medical device companies.

Included within other intangible assets and other assets is $4.1 million related to license manufacturing rights to certain technology from third parties. These intangible assets are classified with other assets in the Company’s consolidated balance sheet and are amortized over their useful life of 15 years.